VIA
RARE icon

Virtus Investment Advisers’s Ultragenyx Pharmaceutical RARE Stock Holding History

Virtus Investment Advisers’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Buy
47,757
+24,455
+105% +$607K 0.37% 112
2026
Q1 		$488K Buy
23,302
+4,440
+24% +$100K 0.13% 222
2025
Q4 		$434K Buy
18,862
+7,551
+67% +$248K 0.12% 239
2025
Q3 		$340K Hold
11,311
– – 0.1% 237
2025
Q2 		$411K Buy
11,311
+3,656
+48% +$132K 0.14% 224
2025
Q1 		$277K Buy
+7,655
New +$318K 0.08% 246

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Virtus Investment Advisers's RARE Position: Q2 2026 in Review

Virtus Investment Advisers increased its Ultragenyx Pharmaceutical (RARE) stake by 105% in Q2 2026, buying an estimated $607K and bringing the position to 47,757 shares worth $1.59M. The position accounts for 0.37% of the portfolio, ranked #112.

Virtus Investment Advisers first reported a position in RARE in Q1 2025 and has held it in 6 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Virtus Investment Advisers held 47,757 shares of Ultragenyx Pharmaceutical worth $1.59M as of Q2 2026.
  • Virtus Investment Advisers bought 24,455 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $607K.
  • Ultragenyx Pharmaceutical made up 0.37% of Virtus Investment Advisers's portfolio in Q2 2026, its #112 holding.
  • Virtus Investment Advisers first reported a position in Ultragenyx Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.